The most common side effects in studies were hypertension (high blood pressure, in 48% of patients), dysphonia (hoarse voice, 27%), fatigue and diarrhoea (both 26%). A hypertensive crisis occurred in 1% of patients.
Tivozanib
Vatalanib
Pegaptanib
Pazopanib
Nintedanib
Abrocitinib
Gilteritinib
Erdafitinib